Vaxart falls on mixed Phase I readout for COVID-19 vaccine; plus BMS-Rockefeller mAb cocktail deal and vaccine updates for Sputnik V, Novavax, Bharat-Ocugen and Sinovac

Vaxart Inc. (NASDAQ:VXRT) lost $13.81 (59%) to $9.52 Wednesday on preliminary Phase I data for VXA-CoV2-1. The data showed the vaccine did evoke CD8⁺ T cell and IgA responses but no detectable serum neutralizing antibodies. Most subjects also did not have detectable IgG responses. The trial of the oral COVID-19 vaccine, and adenoviral vector encoding the spike and nucleocapsid proteins, evaluate single and prime-boost regimens. 

Sinovac seeking conditional authorization of vaccine in China
Sinovac Biotech Ltd. (NASDAQ:SVA) submitted an application to China’s National Medical Products Administration (NMPA) for conditional marketing authorization of CoronaVac. In Phase III trials conducted in Brazil, Indonesia and Turkey, the inactivated SARS-CoV-2 vaccine posted efficacy of 50.4%, 65.3% and 91.3%, respectively. In the Brazilian study, the COVID-19 vaccine completely prevented severe disease and was 78.3% effective against mild cases requiring medical treatment. Similar breakdowns by COVID-19 severity have not been disclosed for the other trials...